文献速递核素与放射性配体治疗

肽受体放射性核素治疗转移性直肠神经内分泌肿瘤疗效高度有利

Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN).
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-10-20

该研究回顾性评估了27例SSTR阳性转移性直肠NEN患者接受PRRT的结局。PRRT后3个月CT疾病控制率为96%,部分缓解70%,中位PFS为29个月,中位OS为81个月,毒性轻微。

要点

  • PRRT后3个月CT疾病控制率达96%,部分缓解占70%。
  • 中位PFS为29个月,中位OS为81个月(中位随访67个月)。
  • 3例出现3级淋巴细胞减少,无显著肾毒性、MDS或白血病。

核心结论

  • PRRT在转移性直肠NEN患者中显示高疗效、形态学缓解和轻微毒性,生存结果非常令人鼓舞。
  • 尽管该队列具有不良预后特征,PRRT仍取得上述结果。
  • 原文建议在该亚组中开展进一步前瞻性PRRT试验。

研究设计与样本

  • 回顾性审查来自两个转诊中心接受PRRT治疗的SSTR阳性转移性直肠NEN患者。
  • 共纳入27例连续患者(男性20例,年龄31-81岁)。
  • PRRT后3个月评估形态学(RECIST 1.1)、SSTR显像反应和毒性。
  • 采用Kaplan-Meier法计算自PRRT开始的无进展生存期(PFS)和总生存期(OS)。

主要发现

  • 70%(19例)为ENETs 2级,3例为3级,1例为1级,4例未记录。
  • 63%(10/16例有可用FDG PET/CT的患者)为FDG avid疾病。
  • 26例因疾病进展接受治疗,多数接受177Lu-DOTA-octreotate,中位累积活度30 GBq,中位4个周期。
  • 14例接受放射增敏化疗(5FU或卡培他滨)。
  • PRRT后3个月CT疾病控制率为96%:部分缓解70%(19/27),稳定疾病26%。

临床怎么用

  • 对于SSTR阳性转移性直肠NEN患者,PRRT可获得高形态学缓解率和疾病控制率。
  • PRRT在该队列中显示轻微毒性,无显著肾毒性、MDS或白血病。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Rectal neuroendocrine neoplasia (NEN) is more common than other NEN origins, but is less commonly metastatic. However, when present, distant disease carries a particularly poor prognosis. Evidence guiding optimal treatment of such patients is lacking. We assessed PRRT outcomes in patients with somatostatin receptor (SSTR) positive metastatic rectal NEN from two referral centres. METHODS: Patients treated with PRRT were retrospectively reviewed. Morphologic (RECIST 1.1), SSTR imaging responses and toxicity were assessed 3 months post-PRRT. Kaplan-Meier estimate was used to determine progression-free survival (PFS) and overall survival (OS) from start of PRRT. RESULTS: Twenty-seven consecutive patients (M = 20, age 31-81 years) were reviewed. The majority (70%) had ENETs grade 2 disease (19 patients), three had Grade 3, one Grade 1, and four not documented. Overall, 63% (10/16 patients with available FDG PET/CT) had FDG avid disease. Twenty-six patients were treated for disease progression. Most had 177Lu-DOTA-octreotate with median cumulative activity of 30 GBq, median four cycles. 14 patients had radiosensitising chemotherapy (5FU or capecitabine). At 3 months post-PRRT, CT disease control rate (DCR) was 96%: partial response was observed in 70% (19/27) and stable disease in 26%. All but one had partial SSTR imaging response. The median PFS was 29 months. Ten patients died, with median overall survival 81 months with a median follow-up of 67 months. Seventeen patients had further treatments after initial PRRT (10 had further cycles of PRRT). Three patients had grade 3 lymphopenia, without significant renal toxicity, MDS or leukaemia. CONCLUSION: Our results indicate high efficacy and morphologic responses with minimal toxicity and very encouraging survival from PRRT in patients with metastatic rectal NEN despite the adverse prognostic features of this cohort. Further prospective PRRT trials are warranted in this subgroup.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kong G, Grozinsky-Glasberg S, Hofman MS, et al. Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN). Eur J Nucl Med Mol Imaging. 2018. PMID: 30343432. doi:10.1007/s00259-018-4196-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。